The lifetime risk of atrial fibrillation (AF) is about 1 in 4 [1] and it has an estimated prevalence of between 2% and 4% in adults [2]. AF is now believed to be a marker of atrial cardiomyopathy 'substrate' that is associated with a prothrombotic state through various mechanisms [3]. The most widely accepted clinical classification of AF is according to temporal rhythm-based patterns, reflecting the notion that most patients initially suffer from transient episodes that prolong over time due to atrial substrate remodelling as the disease progresses; more recently the 4 S-AF scheme has been proposed to characterise AF, and incorporated into guidelines [3, 4].

Other markers of atrial cardiomyopathy such as left atrial dimension and fibrosis have been found to be independently associated with stroke risk [5–7]. Therefore, it may be speculated that patients with extended episodes of 'continuous' AF (persistent, long-standing persistent and permanent AF)
may be at higher risk of stroke complications compared to paroxysmal AF (pAF) due to the degree of underlying cardiomyopathy and also the direct prothrombotic effects of AF per se [8]. Nonetheless, this remains an ill-defined area with previous studies having obtained conflicting results [9–12].

In this study, we assessed the impact of AF type on stroke risk in anticoagulated patients with AF in ‘real-world’ (Murcia AF Project) and ‘clinical trial’ cohorts (AMADEUS [Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation] trial).

**Methods**

We analysed patient-level data from the Murcia AF Project and AMADEUS trial. The design of these studies have formerly been described [13, 14]. Briefly, the Murcia AF Project was an observational study that enrolled consecutive outpatients with AF who were on stable vitamin K antagonist (VKA) therapy (i.e. International Normalised Ratio [INR] of 2.0 to 3.0) during the preceding six months between May and December 2007 in a single-tertiary centre from the Southeast of Spain. The initial period of stable INR was intended to minimise heterogeneity, thus avoiding confounding factors due to differences in the quality of anticoagulation control at study entry. The AMADEUS trial was a multicentre, randomised, open-label non-inferiority study with blinded adjudication of outcomes comparing fixed-dose idraparinux and dose-adjusted VKA in patients with AF [15]. Recruitment occurred between September 2003 and July 2005.

Patients in each cohort were categorised into two groups based on ECG recordings at enrolment using the contemporary temporal rhythm-based classification system [4]. Paroxysmal AF (pAF) was defined as AF that terminates spontaneously or with intervention within seven days of onset. Non-paroxysmal AF (non-pAF) was defined as AF that lasted longer than seven days, including persistent, long-standing persistent and permanent AF subtypes. A complete medical history was documented at inclusion and the recorded parameters were used to determine stroke risk with CHA\textsubscript{2}-DS\textsubscript{2}-VASC score [16] and CARS [17], and bleeding risk with HAS-BLED score [18]. A modified CHA\textsubscript{2}-DS\textsubscript{2}-VASC‘c’ score that applied one additional point a ‘c’ criterion of continuous AF (ie. non-paroxysmal AF) was calculated for each individual patient.

The study endpoint was the incidence rate of ischaemic stroke during follow-up. In the Murcia AF Project, ischaemic stroke was defined as an abrupt onset of focal neurological deficit in a location consistent with the territory of a major cerebral artery due to an obstruction verified by imaging, surgery or autopsy. Major bleeding was defined according to the 2005 International Society on Thrombosis and Haemostasis (ISTH) [19]. All events in the AMADEUS trial were adjudicated by a central committee, who were blinded to original treatment assignment.

**Statistical analyses**

Continuous baseline variables were expressed as median and interquartile range (IQR), and tested for differences with Mann-Whitney U test. Categorical variables were expressed as absolute frequencies and percentages, and tested for differences using chi-squared test. Crude event rates per 100-patient years (PYs) with their Poisson 95% confidence intervals (CIs) were calculated for stroke (and major bleeding) and a comparison between AF types was performed using incidence rate ratio (IRR). This was further analysed according to subgroups of patients based on the CHA\textsubscript{2}-DS\textsubscript{2}-VASC score.

Multivariable Cox proportional hazards model was used to determine the effects of AF type on stroke risk after accounting for potential confounders with the CHA\textsubscript{2}-DS\textsubscript{2}-VASC score, a well-recognised method of risk stratification in AF, and anticoagulation agent for patients in the AMADEUS trial. The predictive performance of the CHA\textsubscript{2}-DS\textsubscript{2}-VASC‘c’ score for stroke events was investigated using receiver-operating characteristic curves, and tested against the CHA\textsubscript{2}-DS\textsubscript{2}-VASC score. C-index was used to reflect the ability of scores to predict events. A two-sided p value of less than 0.05 was considered statistically significant. Analyses were performed using SPSS software version 24.0 (SPSS Inc., Chicago, Illinois, United States) and MedCalc v. 16.4.3 (MedCalc Software bvba, Ostend, Belgium).

**Results**

We included 5,917 patients with AF: 1,361 (23.0%) real-world and 4,556 (77.0%) clinical trial. Real-world patients had a median age of 76 (IQR 71–81) years with 51.3% females compared to a median age of 71 (IQR 64–77) years with 33.5% females among clinical trial participants. Baseline demographics according to AF type for both cohorts are summarised in Table 1. Across both studies, CARS was similar in both groups (p > 0.05). The distribution of CHA\textsubscript{2}-DS\textsubscript{2}-VASC score among patients with non-pAF vs. pAF is shown in Fig. 1. For clinical trial patients on VKA therapy, the median time-in-therapeutic range was 59 (IQR 45–71) in patients with non-pAF and 57 (IQR 44–80) in pAF.
Table 1 Baseline characteristics according to AF type in Real-World and Clinical Trial

| Baseline characteristics                  | Real-World | pAF (n = 1179) | p-value | Clinical Trial | pAF (n = 1634) | p-value |
|-------------------------------------------|------------|---------------|---------|----------------|---------------|---------|
| Age (years), median (IQR)                | 76 (70–81) | 76 (71–81)    | 0.351   | 72 (65–77)     | 70 (63–76)    | <0.001  |
| Female sex, n (%)                        | 104 (54.1) | 594 (50.4)    | 0.089   | 889 (30.4)     | 639 (39.1)    | <0.001  |
| BMI (kgs/m²), median (IQR)               | 29.5 (26.1–32.9) | 29.3 (26.5–32.8) | 0.755   | 28.1 (25.3–31.4) | 27.8 (25.2–31.3) | 0.134   |
| eGFR (ml/min/1.73 m²), median (IQR)      | 69.9 (55.3–84.4) | 71.2 (59.0–86.0) | 0.576   | 86.3 (69.7–94.2) | 85.7 (67.7–93.6) | 0.036   |
| Comorbidities, n (%)                     |            |               |         |                |               |         |
| Anaemia                                   | 36 (19.8)  | 218 (18.5)    | 0.678   | 150 (10.3)     | 96 (11.9)     | 0.240   |
| Coronary artery disease                  | 39 (21.4)  | 216 (18.3)    | 0.317   | 914 (31.3)     | 489 (29.9)    | 0.343   |
| Diabetes mellitus                        | 46 (25.3)  | 317 (26.9)    | 0.647   | 589 (20.2)     | 303 (18.5)    | 0.188   |
| Heart failure                            | 48 (26.4)  | 381 (32.3)    | 0.108   | 817 (28.0)     | 252 (15.4)    | <0.001  |
| Hypertension                             | 149 (81.9) | 967 (82.0)    | 0.961   | 2200 (75.3)    | 1313 (80.4)   | <0.001  |
| Previous ischaemic stroke or TIA         | 41 (22.5)  | 230 (19.5)    | 0.342   | 602 (20.6)     | 363 (22.2)    | 0.201   |
| Risk profile, median (IQR)               |            |               |         |                |               |         |
| CHA₂DS₂-VASc score                       | 4 (3–5)    | 5 (4–6)       | 0.961   | 3 (2–4)        | 3 (2–4)       | 0.009   |
| CARS (%)                                 | 3.7 (2.5–5.7) | 3.8 (2.7–5.6) | 0.980   | 2.9 (2.0–5.0)  | 2.8 (1.9–8.1) | 0.252   |
| HAS-BLED score                           | 2 (2–3)    | 2 (2–3)       | 0.488   | 1 (1–2)        | 2 (1–2)       | 0.112   |

AF, atrial fibrillation; BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; IQR, interquartile range; pAF, paroxysmal AF; TIA, transient ischaemic attack

Stroke and major bleeding rates

During a median follow-up period of 79.1 (IQR 52.2–96.1) months, there were a total of 130 (9.6%) ischaemic stroke and 250 (18.4%) major bleeding events in the real-world. The ischaemic stroke rates in patients with non-pAF and pAF were 1.10 (95% CI 0.59–1.88) per 100PYs and 1.53 (95% CI 1.26–1.83) per 100PYs, respectively (Table 2). There was no significant difference in the crude ischaemic stroke rates between the groups with an IRR of 0.72 (95% CI 0.37–1.28), p = 0.259. This finding was consistent across the various subgroups of patients based on CHA₂DS₂-VASc score (eTable 1). Similarly, major bleeding rates were comparable in both groups with an IRR of 0.95 (95% CI 0.63–1.38), p = 0.791.

Over a median follow-up of 347 (IQR 186–457) days, there were a total of 45 (0.99%) ischaemic stroke and 113 (2.48%) major bleeding events in the clinical trial cohort (Table 2). The ischaemic stroke rates in patients with non-pAF and pAF were 2.29 (95% CI 1.55–3.24) per 100PYs and 0.49 (95% CI 0.27–0.82) per 100PYs, respectively. Participants with non-pAF had a significantly higher crude rate of ischaemic stroke events with an IRR of 4.66 (95% CI 2.41–9.48), p < 0.001. This finding was driven by an excess of ischaemic stroke rates in those with a CHA₂DS₂-VASc score of 4 to 5 (eTable 2). There was also elevated rates of major bleeds among these participants with an IRR of 4.89 (95% CI 3.23–7.55), p < 0.001.

Multivariable analyses

On multivariable analyses, AF type had no significant impact on the ischaemic stroke risk in both real-world (adjusted hazard ratio 1.41 [95% CI 0.80–2.50], p = 0.239) and clinical trial (adjusted hazard ratio 1.16 [95% CI 0.62–2.20], p = 0.646) cohorts, after accounting for known risk factors using the CHA₂DS₂-VASc score and anticoagulation agent for clinical trial patients (Table 3).

Predictive performance of CHA₂DS₂-VASc’ vs. CHA₂DS₂-VASc

The predictive performance of the CHA₂DS₂-VASc’ score was modest in both the real-world (c-index 0.623 [95% CI 0.596–0.648]) and clinical trial (c-index 0.673 [95% CI 0.659–0.687]) (Fig. 2). There was no significant improvement in the CHA₂DS₂-VASc’ score compared to CHA₂DS₂-VASc score in either cohort (p > 0.05).

Discussion

In this study of anticoagulated patients with AF, we found that patients with non-pAF had elevated ischaemic stroke rates in the clinical trial but not in the real-world setting. Second, rates in the former patient cohort was attributable to the presence of underlying risk factors rather than the presence of non-pAF itself, as reinforced by the higher crude risk of major bleeding. Third, inclusion of ‘continuous/
chronicity of AF’ into the CHA$_2$DS$_2$-VASc score resulted in a minimal and non-significant improvement in the predictive performance of this model in both cohorts.

The findings presented here are consistent with other real-world studies and clinical trials. A sub-study of 6,706 patients in the ACTIVE W trial that compared oral anticoagulation (OAC) to combined antiplatelet therapy in AF showed no significant difference in the annual risk of thromboembolic events based on AF type [20]. Nevertheless, the authors only accounted for risk factors within the conventional CHADS$_2$ score, thereby increasing the likelihood of residual confounders for stroke. Data from the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry that compared 1-year outcomes among AF patients found that non-pAF was not independently associated with all-cause mortality, stroke or transient ischaemic attack, or major bleeding after a comprehensive adjustment for other risk factors [21]. The results were corroborated in a retrospective observational study of 7,156 patients with AF from the Loire Valley Atrial Fibrillation Project [10], though both studies were predominantly comprised of a cohort of European patients which may limit the generalisability of the reported outcomes. In this regard, a study of Asian patients in the Chinese Atrial Fibrillation Registry (CAFR) also demonstrated that AF type was not independently associated with thromboembolic risk [22].

In contrast to the aforementioned studies, Cho et al. reported that among 8,883 real-world patients with AF, those with non-pAF were older, male-predominant and had a higher prevalence of comorbidities which ultimately led to an increase in anticoagulation prescription and rhythm control treatment compared to those with pAF [9]. After accounting for these and other factors, the risk of ischaemic stroke remained 2-fold higher in patients with non-pAF compared to pAF over a follow-up period of 17 months.

Nonetheless, the results may have been influenced by a low uptake of OAC, despite a high proportion of patients with at least a CHA$_2$DS$_2$-VASc score of 2, and the relatively low incidence of stroke in general. A pooled analysis of participants from the ACTIVE-A and AVERROES trials found that the pattern of AF was a strong independent predictor of stroke risk [12]. However, for inclusion into both these trials, participants had to be deemed unsuitable for VKA (or OAC) and there were no participants with a CHA$_2$DS$_2$-VASc score of 0 (or 1 in females), thus restricting clinical applicability of the results. An earlier meta-analysis of 99,996 patients from 12 studies reported that non-pAF was associated with a 1.4-fold and 1.5-fold increase in thromboembolism and mortality, respectively, even after multivariable adjustment with no significant difference in the rates of major bleeding [23].

Although the current clinical classification of AF is practical and widely adopted, some of the conflicting results in relation to stroke risk may be attributable to the inherent limitations of this system. For example, it has a poor ability to discriminate between AF patients on the basis of stage and severity of the underlying disease [24]. Furthermore, with the infrequent utilisation of continuous cardiac monitoring in most prior studies, the findings were likely subject to misclassification bias as the diagnosis of AF type was primarily reliant on the presence of patient-reported symptoms and snapshots of electrocardiographic tracings performed...
Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial

Fig. 2 Receiver operating characteristic curves of CHA₂DS₂-VASc vs. CHA₂DS₂-VASc’ scores in Real-World and Clinical Trial. Blue line = CHA₂DS₂-VASc; Red line = CHA₂DS₂-VASc’. C-index comparison: Real-World (p = 0.312); Clinical Trial (p = 0.954).

Conclusions

Overall, our results support the need for anticoagulation based on thromboembolic risk profile rather than AF type. We did not find an association between the temporal rhythm-based patterns of AF and stroke risk in anticoagulated patients, suggesting that this should not be a consideration when assessing the need for anticoagulation in AF and that the presence of pAF (over non-pAF) should not offer false reassurance to clinicians. Rather, the focus should remain on identifying low-risk patients using proven stroke risk factors within the CHA₂DS₂-VASc score.

Supplementary Information

The online version contains supplementary material available at [https://doi.org/10.1007/s11239-022-02638-0](https://doi.org/10.1007/s11239-022-02638-0).

Acknowledgements

None.

Disclosures

WYD, JMRC, FM and VR: None declared. GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseau and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. All authors approved the final version of the submitted manuscript. Author contributions: WYD and GYHL contributed to study conception and design. WYD and JMRC contributed to data analysis, interpretation of data, and drafted the manuscript. FM, VR and GYHL revised the manuscript critically for important intellectual content.

Funding sources

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and material

The data that support the findings of this study are available from the corresponding author, GYHL, upon reasonable request.

Code Availability

Not applicable.

Declarations

Ethics approval: Patients provided written informed consent; the AMADEUS study protocol was approved by the appropriate ethics review boards.

Consent to participate: See above.

Consent for publication: See above.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

References

1. Heeringa J, van der Kuip DAM, Hofman A et al (2006) Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 27:949–953. [https://doi.org/10.1093/eurheartj/ehi825](https://doi.org/10.1093/eurheartj/ehi825)
2. Benjamin EJ, Muntner P, Alonso A et al (2019) Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation 139:e56–e528. https://doi.org/10.1161/CIR.000000000000659

3. Potpara TS, Lip GYH, Blomstrom-Lundqvist C et al (2021) The 4S-AF Scheme (Stroke Risk; Symptoms; Severity of Burden; Substrate): A Novel Approach to In-Depth Characterization (Rather than Classification) of Atrial Fibrillation. Thromb Haemost 121:270–278. https://doi.org/10.1055/s-0040-1716408

4. Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 42:373–498. https://doi.org/10.1093/eurheartj/ehaa612

5. Xu Y, Zhao L, Zhang L et al (2020) Left Atrial Enlargement and the Risk of Stroke: A Meta-Analysis of Prospective Cohort Studies. Front Neurol 11:26

6. King JB, Azadani P, Sukucesanj B et al (2017) Left Atrial Fibrosis and Risk of Cerebrovascular and Cardiovascular Events in Patients With Atrial Fibrillation. J Am Coll Cardiol 70:1311–1321. https://doi.org/10.1016/j.jacc.2017.07.758

7. Goette A, Kalman JM, Aguina L et al (2016) EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardioembolopathies: definition, characterization, and clinical implication. Europace 18:1455–1490. https://doi.org/10.1093/europace/euw161

8. Ding WY, Gupta D, Lip GYH (2020) Atrial fibrillation and the prothrombotic state: revisiting Virchow's triad in 2020. Heart 106:1463–1468. https://doi.org/10.1136/heartjnl-2020-316977

9. Cho S, Kim J, Kim J-B et al (2020) The difference of burden of ectopic beats in different types of atrial fibrillation and the effect of atrial fibrillation type on stroke risk in a prospective cohort of patients with atrial fibrillation (CODE-AF registry). Sci Rep 10:6319. https://doi.org/10.1038/s41598-020-63370-4

10. Banerjee A, Taulander S, Olesen JB et al (2013) Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. Int J Cardiol 167:2682–2687. https://doi.org/10.1016/j.ijcard.2012.06.118

11. Al-Khatib SM, Thomas L, Wallentin L et al (2013) Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. Eur Heart J 34:2464–2471. https://doi.org/10.1093/eurheartj/eht135

12. Vanassense T, Lauw MN, Eikelboom JW et al (2015) Risk of ischemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. Eur Heart J 36:281–287a. https://doi.org/10.1093/eurheartj/ehu307

13. Rivero-Caravaca JM, Esteve-Pastor MA, Marin F et al (2018) A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the “Real-World” vs Clinical Trials. Mayo Clin Proc 93:1065–1073. https://doi.org/10.1016/j.mayocp.2018.01.028

14. Ding WY, Lip GYH, Pastori D, Shantsila A (2020) Effects of Atrial Fibrillation and Chronic Kidney Disease on Major Adverse Cardiovascular Events. Am J Cardiol 132:72–78. https://doi.org/10.1016/j.amjcard.2020.07.004

15. Bousser MG, Bouthier J, Buller HR et al (2008) Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 371:315–321. https://doi.org/10.1016/S0140-6736(08)60168-3

16. Lip GYH, Nieuwlaat R, Pisters R et al (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on atrial fibrillation. Chest 137:263–272. https://doi.org/10.1378/chest.09-1584

17. Lee CJ-Y (2020) Calculator of Absolute Stroke Risk. https://hjerteforeningen.shinyapps.io/riskvisr/

18. Pisters R, Lane DA, Nieuwlaat R et al (2010) A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 138:1093–1100. https://doi.org/10.1378/chest.10-0134

19. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antithrombotic medicinal products in non-surgical patients. J Thromb Haemost 3:692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.x

20. Hohnloser SH, Pajitnev D, Pogue J et al (2007) Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 50:2156–2161. https://doi.org/10.1016/j.jacc.2007.07.076

21. Boriani G, Laroche C, Diemenger I et al (2016) “Real-world” management and outcomes of patients with paroxysmal vs. non-paroxysmal atrial fibrillation in Europe: the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) General Pilot Registry. Europace 18:648–657. https://doi.org/10.1093/europe/eur390

22. Wang Y, Ma C-S, Du X et al (2019) Thromboembolic risks associated with paroxysmal and persistent atrial fibrillation in Asian patients: a report from the Chinese atrial fibrillation registry. BMC Cardiovasc Disord 19:283. https://doi.org/10.1186/s12872-019-1260-7

23. Ganesan AN, Chew DP, Hartshorne T et al (2016) The impact of atrial fibrillation type on the risk of thromboembolism, mortality, and bleeding: a systematic review and meta-analysis. Eur Heart J 37:1591–1602. https://doi.org/10.1093/eurheartj/ehw007

24. Lubitz SA, Benjamin EJ, Ruskin JN et al (2010) Challenges in the classification of atrial fibrillation. Nat Rev Cardiol 7:451–460. https://doi.org/10.1038/nrcardio.2010.86

25. Dekker LR, Pokushalov E, Sanders P et al (2016) Continuous den; Substrate): A Novel Approach to In-Depth Characterization of Patients With Atrial Fibrillation. J Am Coll Cardiol 70:1311–1321. https://doi.org/10.1016/j.jacc.2017.07.758

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.